Serialisation: When quick fixes disappoint

Many manufacturers and contract packagers had to learn it the hard way: serialisation is much more than just placing serial numbers on pharmaceutical packaging. During the FMD implementation rush, some companies relied on quick solutions. However, quick fixes did not live up to what they promised and gave manufacturers manifold reasons for disappointment, from lack of interoperability and compliance issues to high operational complexity, to name just a few.

read more

Video: Traceable Quality System

VISIT THE INNOVATION CENTRE

TQS Technology Highlights

With its Traceable Quality System, WIPOTEC-OCS supports pharmaceutical manufacturers in achieving compliance with serialisation and Track & Trace regulations in the EU and many different countries worldwide. The company has developed a broad range of high-quality serialisation and aggregation solutions that, due to their modular design, can be highly customised to any application requirements. Pharmaceutical manufacturers and packagers worldwide appreciate these solutions for their flexibility, high-level interoperability and standardised interfaces.

read more

Improving supply chain transparency through aggregation

Forward-thinking pharmaceutical companies that have already equipped their lines with serialisation technology can even trace the movement of their products in the supply chain by deploying aggregation. Enhanced product traceability enabled through aggregation helps companies prevent product diversion by automating data exchange between the manufacturer and their trade partners. Especially in times of crisis, such as the current COVID-19 pandemic, aggregation is more relevant than ever. Reliable distribution of pharmaceuticals depends on supply chain transparency and automated data flows. Additionally, aggregation improves the decommissioning of shipping cases and pallets, as well as facilitating efficient product recalls or returns. What is more, aggregation is an integral part of a go-to-market strategy for manufacturers who intend to export pharmaceuticals to countries requiring track and trace, for example, Russia, Turkey, the US or China.

To find out in more detail about the benefits of aggregation for pharmaceutical companies, and see what countries require or plan to mandate aggregation, read the related white paper.

download the white paper

About WIPOTEC-OCS

WIPOTEC-OCS is a sales and service company for dynamic, high-precision weighing, inspection solutions, serialisation and Track-& Trace technology. As a wholly owned subsidiary of the high-tech specialist WIPOTEC, which develops and produces all machinery solutions at its headquarters in German Kaiserslautern, WIPOTEC-OCS has been setting global standards in the production lines of leading manufacturers for more than 30 years.

Enabling serialisation while maintaining high production efficiency is one of the significant advantages of the time-tested Track-&-Trace solutions. More than 3,000 manufacturers across every continent trust in the company’s know-how, technological leadership and passion for innovating.

The company keeps its finger on the pulse of the global regulatory requirements to ensure timely updates of its solutions according to the latest requirements in any country worldwide. As an official GS1 Solution Partner, the company is taking an active role in shaping compliance provisions and providing technical guidance and support on their technical implementation. As a member of the OPEN-SCS working group, the company is committed to the standardisation of communication interfaces between different serialisation and data management systems.

GET IN TOUCH NOW

Go to article: Home | Pause for thoughtGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: NewsGo to article: BaxterGo to article: Covid-19 executive briefing by GlobalDataGo to article: ELPRO Monitoring SolutionsGo to article: Abivax’s ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for successGo to article: Abiomed’s Impella receives FDA Emergency Use Authorization during Covid-19Go to article: FargoGo to article: Disruptions to global oncology trials have fallen to a three-month lowGo to article: MimotopesGo to article: AstraZeneca/Oxford University and CanSino publish promising Covid-19 vaccine cliGo to article: Biotech IPO valuation relies on data to enter capital markets during Covid-19 paGo to article: Nelson LabsGo to article: The pharma industry briefingGo to article: Pfeiffer VacuumGo to article: A century of cultures: celebrating the world’s oldest lab culture collectionGo to article: SkyepharmaGo to article: Gut feeling: exploring the therapeutic potential of the gut-brain axisGo to article: OptelGo to article: Crabby concoctions: why pharma’s thirst for crustacean blood is up for debateGo to article: Air FranceGo to article: Debunking myths about puberty blockers for transgender childrenGo to article: MicronovaGo to article: Hiring from home: pharma recruitment in the age of Covid-19 Go to article: Nipro PharmapackagingGo to article: Q&A: breaking new ground in pharma packaging with HoneywellGo to article: WipotecGo to article: Treatment-resistant rare diseases: exploring landmark drug approvals in 2020Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Modernising pharma patents: can AI be an inventor?Go to article: ILC Dover Go to article: Boosting agility to accelerate project timescales Go to article: Scandinavian HealthGo to article: Doing the right thing: the enhanced case for complianceGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue